TAKEDA PHARMACEUTICAL COMPANY LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 67.69 BRL | -2.22% |
|
0.00% | -2.13% |
| May. 16 | Takeda Canada Completes LOI Stage for Post-Transplant Cytomegalovirus Treatment | MT |
| May. 15 | Takeda Pharmaceutical's Dengue Vaccine Granted WHO Prequalification | MT |
| Sales 2024 | 4,264B 27.16B 141B | Sales 2025 * | 4,135B 26.35B 136B | Capitalization | 6,486B 41.32B 214B |
|---|---|---|---|---|---|
| Net income 2024 | 144B 918M 4.75B | Net income 2025 * | 136B 865M 4.47B | EV / Sales 2024 | 1.54 x |
| Net Debt 2024 * | 3,771B 24.02B 124B | Net Debt 2025 * | 4,125B 26.28B 136B | EV / Sales 2025 * | 2.57 x |
| P/E ratio 2024 |
45.4
x | P/E ratio 2025 * |
45.8
x | Employees | 49,095 |
| Yield 2024 * |
4.55% | Yield 2025 * |
4.62% | Free-Float | 99.12% |
More Fundamentals
* Assessed data
More news
Latest transcript on Takeda Pharmaceutical Company Limited
More recommendations
More press releases
More news
| 1 day | -2.22% | ||
| Current month | +0.18% | ||
| 1 month | +0.18% | ||
| 3 months | -5.75% | ||
| 6 months | -2.03% | ||
| Current year | -2.13% |
1 week
67.62
67.83
1 month
66.4669.09
Current year
66.4674.20
1 year
66.4692.00
3 years
66.1092.00
5 years
66.1092.00
10 years
66.1092.00
| Managers | Title | Age | Since |
|---|---|---|---|
Christophe Weber
CEO | Chief Executive Officer | 57 | 14-03-31 |
Gabriele Ricci
CTO | Chief Tech/Sci/R&D Officer | 45 | 22-01-31 |
Mwana Lugogo
CMP | Compliance Officer | 54 | 11-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 71 | 16-05-31 | |
Ian Clark
BRD | Director/Board Member | 62 | 18-12-31 |
Steven Gillis
BRD | Director/Board Member | 71 | 18-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-24 | 67.69 | -0.21% | 14 |
| 24-05-22 | 67.83 | +0.21% | 9 |
| 24-05-21 | 67.69 | 0.00% | 2 |
Delayed Quote Sao Paulo, May 24, 2024 at 03:04 pm EDT
More quotes
Takeda Pharmaceutical Company Limited specializes in the development, manufacturing and marketing of pharmaceutical products especially for metabolic and cardiovascular diseases, cancers and central nervous systems troubles. The activity is organized around 2 areas:
- sale of drugs and consumer care products;
- services.
Net sales are distributed geographically as follows: Japan (17.5%), Asia (5%), the United States (49%), Europe and Canada (20.8%), Latin America (3.8%), Russia and CIS (1.8%) and other (2.1%).
Sector
Pharmaceuticals
Calendar
2024-06-03
- Sleep Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
18
Last Close Price
4,134
JPY
Average target price
4,807
JPY
Spread / Average Target
+16.28%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +38.51% | 727B | |
| +33.05% | 599B | |
| -6.23% | 354B | |
| +18.78% | 328B | |
| +1.35% | 277B | |
| +16.00% | 243B | |
| +8.09% | 205B | |
| -5.77% | 203B | |
| +6.19% | 164B |
- Stock Market
- Equities
- 4502 Stock
- TAKP34 Stock
